A new study published in the Global Spine Journal, one of the most respected journals in spine and orthopedics research, highlights the superior effectiveness of Apos® in managing chronic low back pain (CLBP).
The study, conducted in partnership with Matthew N. Bartels, MD, MPH, Chairman of Rehabilitation Medicine and Professor of Physical Medicine and Rehabilitation at Montefiore Einstein, was a randomized controlled trial (RCT) that compared Apos®, an FDA-registered, non-invasive personalized footworn medical device with traditional physical therapy (PT), for treatment of chronic low back pain (CLBP).
Given the limited long-term effectiveness of existing non-surgical CLBP interventions, this study positions Apos® as a clinically validated treatment option that can deliver meaningful and sustained benefits for patients.
Study Overview
The trial involved 162 participants, who were randomly assigned to one of the two treatment groups and monitored over 12 months. The study used pain reduction, functional ability, and quality of life as primary outcome measures.
Key Findings
- Pain Reduction: Patients using Apos® experienced an average pain reduction of 56%, compared to a 26% decrease in the Physical Therapy group.
- Function and Quality of Life: The Apos® group demonstrated superior improvements in daily functional ability and overall quality of life.
“These findings underscore the long-term efficacy of Apos®, which exceeds the outcomes typically associated with non-surgical treatments for chronic low back pain, and the potential for Apos® to transform chronic low back pain management by offering a scientifically validated, non-invasive alternative that delivers superior outcomes,” said Ganit Segal, MPE, MBA, EVP, Chief Science & Innovation Officer at AposHealth.
The results suggest that use of a personalized footworn medical device can potentially improve long-term outcomes and quality of life for people experiencing chronic low back pain.
